MORGAN STANLEY - HTG MOLECULAR DIAGNOSTICS IN ownership

HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H203. A total of 20 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
MORGAN STANLEY ownership history of HTG MOLECULAR DIAGNOSTICS IN
ValueSharesWeighting
Q3 2022$7,000
-30.0%
10,611
+5.9%
0.00%
Q2 2022$10,000
-52.4%
10,023
-32.1%
0.00%
Q1 2022$21,000
+40.0%
14,763
+421.7%
0.00%
Q4 2021$15,000
-37.5%
2,830
-32.9%
0.00%
Q3 2021$24,000
-87.0%
4,219
-86.7%
0.00%
Q2 2021$184,000
+2200.0%
31,668
+2179.9%
0.00%
Q1 2021$8,000
-42.9%
1,389
-49.9%
0.00%
Q4 2020$14,0002,7720.00%
Other shareholders
HTG MOLECULAR DIAGNOSTICS IN shareholders Q3 2022
NameSharesValueWeighting ↓
Virtu Financial LLC 72,452$44,0000.00%
HighMark Wealth Management LLC 6,966$4,0000.00%
UBS Group AG 26$00.00%
WELLS FARGO & COMPANY/MN 46$00.00%
CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0$00.00%
GEODE CAPITAL MANAGEMENT, LLC 47,178$28,0000.00%
STATE STREET CORP 14,455$9,0000.00%
MILLENNIUM MANAGEMENT LLC 23,683$15,0000.00%
MORGAN STANLEY 10,611$7,0000.00%
BlackRock Inc. 74,192$45,0000.00%
View complete list of HTG MOLECULAR DIAGNOSTICS IN shareholders